BMS Bets On Amira's IPF Drug In $325M Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.
You may also be interested in...
Deals of the Week: Is Astex Settling For An Underpriced Buyout?
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
Fibrosis/Cancer Start-up Seeded By Celgene Begins To Take Shape
Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.
GSK Gains T-Cell Vaccine Tech With €250 Million Okairos Acquisition
The British pharma has done the biggest takeout of a private, clinical-stage European biotech so far this year. It is focused on a Phase I RSV vaccine and a T-cell stimulating technology. As for VCs, they have nabbed roughly a 10x return on their invested capital.